Smallpox/Monkeypox Vaccine (JYNNEOS™) Administration, Eligibility, and Availability in Tennessee

General Vaccine Information: There are currently 2 vaccines licensed by the FDA for monkeypox: JYNNEOS (aka Imvamune or Imvanex) and ACAM2000.

JYNNEOS
- This vaccine will be supplied in a single dose vial which should be thawed before use. Once thawed, the vaccine may be kept at 2°C to 8°C (+36°F to +46°F) for 8 weeks after thawed. Do not refreeze.
- This vaccine is a two-dose series, with the second vaccine being administered 28 days after the first.

Eligibility for JYNNEOS
- Vaccination is available to Tennessee residents who meet the CDC’s eligibility criteria, prioritizing those most at risk of exposure to someone with monkeypox.
- Please see CDC’s eligibility criteria below:
  - Standard post-exposure prophylaxis (PEP), administration of JYNNEOS within 4 days of known exposure to monkeypox to avoid infection or between 4- and 14-days post-exposure to reduce severity of symptoms. Exposed individuals receiving vaccine will need to self-monitor for symptoms and prepare to isolate.
  - In addition to PEP, the PEP++ approach aims to reach individuals who are at high risk of exposure to monkeypox for post-exposure prophylaxis, even if they have not had documented exposure to someone with confirmed monkeypox. When coupled with self-isolation and other prevention measures, PEP++ may help slow the spread of the disease.
  - Gay, bisexual, or other men who have sex with men (MSM), and/or transgender, gender-nonconforming or gender non-binary individuals who report any of the following in the last 90 days (pre-exposure prophylaxis/PrEP)
    - Having multiple sex partners or anonymous sex
    - Being diagnosed with a sexually transmitted infection (STI) or HIV
    - Living with HIV
    - Receiving medications to prevent HIV infection (HIV PrEP)

Availability of JYNNEOS
- Contact your local health department to discuss availability of the JYNNEOS vaccine if you have a patient who may have been exposed to monkeypox.
- Please be aware that there is currently a limited supply of JYNNEOS, and vaccination is prioritized for individuals at highest risk of exposure to someone with monkeypox.
- In the future, we expect eligibility criteria to expand as allocation increases.

ACAM2000
- Please note that the ACAM2000 vaccine is available in greater quantities in the strategic national stockpile of JYNNEOS vaccine.
- ACAM2000 is administered as one percutaneous dose via multiple puncture technique with a bifurcated needle.
- Following a successful inoculation, a lesion (known as a “take”) will develop at the site of the vaccination; the lesion may take up to 6 weeks or more to heal. The take can be spread to other parts of the body or even to other people.
ACAM2000 should not be given to people with the following conditions: cardiac disease; eye disease treated with topical steroids; congenital or acquired immune deficiency disorders, including those taking immunosuppressive medications and people living with HIV (regardless of immune status); atopic dermatitis/eczema and persons with a history of atopic dermatitis/eczema or other acute or exfoliative skin conditions; infants less than 12 months of age; pregnancy

At this time, TDH is not pursuing the deployment of ACAM2000 due to these factors.